---
title: "Revance Therap (RVNC.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/RVNC.US.md"
symbol: "RVNC.US"
name: "Revance Therap"
industry: "Pharmaceuticals"
datetime: "2026-03-13T17:40:20.196Z"
locales:
  - [en](https://longbridge.com/en/quote/RVNC.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/RVNC.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/RVNC.US.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/quote/RVNC.US.md) | [繁體中文](https://longbridge.com/zh-HK/quote/RVNC.US.md)


# Revance Therap (RVNC.US)

## Company Overview

Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis. It is also developing OnabotulinumtoxinA, a biosimilar to BOTOX that is in preclinical stage. The company also offers Resilient Hyaluronic Acid (RHA) dermal filler for the correction of moderate to severe dynamic facial wrinkles; and RHA Redensity, a dermal filler for the treatment of moderate to severe dynamic perioral rhytids.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | US Market |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: C
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-03-13T04:30:15.000Z

**Overall: C (0.48)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 0 / 188 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Blend - Stocks in which the company has both growth and mature businesses.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

**Multi Score**: C

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 25.82% |  |
| Net Profit YoY | 55.48% |  |
| P/B Ratio | 0.00 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 0.00 |  |
| Revenue | 256945000.00 |  |

#### Multi Score Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 225.10% | A |
| Profit Margin | -71.78% | E |
| Gross Margin | 51.55% | B |
| Revenue YoY | 25.82% | A |
| Net Profit YoY | 55.48% | B |
| Total Assets YoY | -13.32% | E |
| Net Assets YoY | -53.51% | E |
| Cash Flow Margin | -139.31% | D |
| OCF YoY | 25.82% | A |
| Turnover | 0.52 | C |
| Gearing Ratio | 135.32% | E |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Revance Therap",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "25.82%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "55.48%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "0.00",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "256945000.00",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "C",
      "indicators": [
        {
          "name": "ROE",
          "value": "225.10%",
          "rating": "A"
        },
        {
          "name": "Profit Margin",
          "value": "-71.78%",
          "rating": "E"
        },
        {
          "name": "Gross Margin",
          "value": "51.55%",
          "rating": "B"
        },
        {
          "name": "Revenue YoY",
          "value": "25.82%",
          "rating": "A"
        },
        {
          "name": "Net Profit YoY",
          "value": "55.48%",
          "rating": "B"
        },
        {
          "name": "Total Assets YoY",
          "value": "-13.32%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-53.51%",
          "rating": "E"
        },
        {
          "name": "Cash Flow Margin",
          "value": "-139.31%",
          "rating": "D"
        },
        {
          "name": "OCF YoY",
          "value": "25.82%",
          "rating": "A"
        },
        {
          "name": "Turnover",
          "value": "0.52",
          "rating": "C"
        },
        {
          "name": "Gearing Ratio",
          "value": "135.32%",
          "rating": "E"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| Dividend Yield | 0.00% | - | - | - | - |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Eli Lilly (LLY.US) | A | A | B | E | B | B |
| 02 | ROCHE HOLDINGS AG (RHHVF.US) | A | B | B | D | C | B |
| 03 | Roche (RHHBY.US) | A | B | B | D | C | B |
| 04 | AstraZeneca (AZN.US) | A | B | C | D | C | B |
| 05 | NOVARTIS AG (NVS.US) | A | B | C | D | C | B |

## Institutional View

### Analyst Rating Distribution

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 3.65 |
| Highest Target | 25.00 |
| Lowest Target | 3.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/RVNC.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/RVNC.US/norm.md)
- [Related News](https://longbridge.com/en/quote/RVNC.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/RVNC.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**